Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Jul-03-22 | Apr-03-22 | Jan-02-22 | Oct-03-21 | Jul-04-21 | Apr-04-21 | Jan-03-21 | Sep-27-20 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| Pharmaceutical | 13,317.0 | 12,869.0 | 14,288.0 | 12,994.0 | 12,480.0 | 12,101.0 | 12,268.0 | 11,418.0 |
| Medical Devices | | | 6,859.0 | 6,644.0 | | | 6,589.0 | 6,150.0 |
| Other | 10,703.0 | 10,557.0 | 3,657.0 | 3,700.0 | 10,832.0 | 10,220.0 | 3,618.0 | 3,514.0 |
| Total revenues | 24,020.0 | 23,426.0 | 24,804.0 | 23,338.0 | 23,312.0 | 22,321.0 | 22,475.0 | 21,082.0 |
| Revenue growth [+] | 3.0% | 5.0% | 10.4% | 10.7% | 27.1% | 7.9% | 8.3% | 1.7% |
| Pharmaceutical | 6.7% | 6.3% | 16.5% | 13.8% | 16.1% | 8.7% | 16.3% | 5.0% |
| Medical Devices | | | 4.1% | 8.0% | | | -0.6% | -3.7% |
| Cost of goods sold | 7,919.0 | 7,598.0 | 7,955.0 | 7,250.0 | 7,587.0 | 7,063.0 | 7,814.0 | 6,972.0 |
| Gross profit | 16,101.0 | 15,828.0 | 16,849.0 | 16,088.0 | 15,725.0 | 15,258.0 | 14,661.0 | 14,110.0 |
| Gross margin | 67.0% | 67.6% | 67.9% | 68.9% | 67.5% | 68.4% | 65.2% | 66.9% |
| Selling, general and administrative [+] | 6,226.0 | 5,938.0 | 7,154.0 | 6,000.0 | 6,073.0 | 5,432.0 | 6,457.0 | 5,431.0 |
| General and administrative | | | 7,154.0 | | | | 6,457.0 | |
| Research and development | 3,703.0 | 3,462.0 | 4,720.0 | 3,422.0 | 3,394.0 | 3,178.0 | 4,032.0 | 2,840.0 |
| EBITDA [+] | 7,916.0 | 8,197.0 | 6,818.0 | 8,480.0 | 8,097.0 | 8,542.0 | 6,112.0 | 7,657.0 |
| EBITDA growth | -2.2% | -4.0% | 11.6% | 10.7% | 40.0% | 12.5% | -0.7% | 0.5% |
| EBITDA margin | 33.0% | 35.0% | 27.5% | 36.3% | 34.7% | 38.3% | 27.2% | 36.3% |
| Depreciation | 644.0 | 669.0 | 743.0 | 614.0 | 639.0 | 694.0 | 640.0 | 618.0 |
| EBITA | 7,272.0 | 7,528.0 | 6,075.0 | 7,866.0 | 7,458.0 | 7,848.0 | 5,472.0 | 7,039.0 |
| EBITA margin | 30.3% | 32.1% | 24.5% | 33.7% | 32.0% | 35.2% | 24.3% | 33.4% |
| Amortization of intangibles | 1,100.0 | 1,100.0 | 1,100.0 | 1,200.0 | 1,200.0 | 1,200.0 | 1,300.0 | 1,200.0 |
| EBIT [+] | 6,172.0 | 6,428.0 | 4,975.0 | 6,666.0 | 6,258.0 | 6,648.0 | 4,172.0 | 5,839.0 |
| EBIT growth | -1.4% | -3.3% | 19.2% | 14.2% | 54.3% | 13.7% | -3.9% | -0.8% |
| EBIT margin | 25.7% | 27.4% | 20.1% | 28.6% | 26.8% | 29.8% | 18.6% | 27.7% |
| Non-recurring items [+] | 85.0 | 680.0 | 83.0 | 960.0 | 56.0 | 53.0 | 97.0 | 206.0 |
| In-process research & development | | 610.0 | | 900.0 | | | 37.0 | 138.0 |
| Interest expense, net [+] | -26.0 | -12.0 | 47.0 | 7.0 | 28.0 | 48.0 | 74.0 | 32.0 |
| Interest expense | 38.0 | 10.0 | 60.0 | 20.0 | 40.0 | 63.0 | 87.0 | 44.0 |
| Interest income | 64.0 | 22.0 | 13.0 | 13.0 | 12.0 | 15.0 | 13.0 | 12.0 |
| Other income (expense), net | -273.0 | 102.0 | -9.0 | -1,850.0 | 488.0 | 882.0 | -2,354.0 | -1,200.0 |
| Pre-tax income | 5,840.0 | 5,862.0 | 4,836.0 | 3,849.0 | 6,662.0 | 7,429.0 | 1,647.0 | 4,401.0 |
| Income taxes | 1,026.0 | 713.0 | 100.0 | 182.0 | 384.0 | 1,232.0 | -91.0 | 847.0 |
| Tax rate | 17.6% | 12.2% | 2.1% | 4.7% | 5.8% | 16.6% | | 19.2% |
| Net income | 4,814.0 | 5,149.0 | 4,736.0 | 3,667.0 | 6,278.0 | 6,197.0 | 1,738.0 | 3,554.0 |
| Net margin | 20.0% | 22.0% | 19.1% | 15.7% | 26.9% | 27.8% | 7.7% | 16.9% |
| |
| Basic EPS [+] | $1.83 | $1.96 | $1.80 | $1.39 | $2.38 | $2.35 | $0.66 | $1.35 |
| Growth | -23.2% | -16.8% | 172.6% | 3.2% | 73.2% | 7.0% | -56.5% | 102.9% |
| Diluted EPS [+] | $1.80 | $1.93 | $1.77 | $1.37 | $2.35 | $2.32 | $0.65 | $1.33 |
| Growth | -23.2% | -16.7% | 172.2% | 3.0% | 72.7% | 6.9% | -56.4% | 102.8% |
| |
| Dividends per share [+] | $1.13 | $1.06 | $1.06 | $1.06 | $1.06 | $1.01 | $1.01 | $1.01 |
| Growth | 6.6% | 4.9% | 5.0% | 5.0% | 5.0% | 6.2% | 6.8% | 6.5% |
| |
| Shares outstanding (basic) [+] | 2,629.6 | 2,629.2 | 2,632.1 | 2,632.6 | 2,632.5 | 2,631.6 | 2,632.8 | 2,632.5 |
| Growth | -0.1% | -0.1% | 0.0% | 0.0% | 0.0% | -0.1% | -0.5% | -0.1% |
| Shares outstanding (diluted) [+] | 2,667.9 | 2,666.5 | 2,674.0 | 2,674.9 | 2,671.6 | 2,672.7 | 2,670.7 | 2,669.3 |
| Growth | -0.1% | -0.2% | 0.1% | 0.2% | 0.2% | 0.1% | -0.5% | 0.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|